Mechanisms of aluminium neurotoxicity in oxidative stress-induced ...
Mechanisms of aluminium neurotoxicity in oxidative stress-induced ... Mechanisms of aluminium neurotoxicity in oxidative stress-induced ...
REFERENCES Hamilton E. I., Miniski M. J. and Cearly J. J. (1973) The concentration and distribution of some 202 stable elements in healthy human tissues from the United Kingdom: An environmental study. Sci. Total Environ. 1, 341–374. Hantson P., Mahieu P., Gersdorff M., Sindic C. J. and Lauwerys R. (1994) Encephalopathy with seizures after use of aluminium-containing bone cement. Lancet 344, 1647. Haque E. M., Thomas K. J., D’Souza C., Callaghan S., Kitada T., Slack R. S., Fraser P., Cookson M. R., Tandon A. and Park D. S. (2008) Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 105, 1716–1721. Harris W. R., Berthon G., Day J. P., Exley C., Flaten T. P., Forbes W. F., Kiss T., Orvig C. and Zatta P. F. (1996) Speciation of aluminum in biological systems. J. Toxicol. Environ. Health. 48, 543–568. Harris W. R., Berthon G., Day J. P., Exley C., Flaten T. P., Forbes W. F., Kiss T., Orvig C. and Zatta P. F. (1997) Speciation of aluminum in biological systems, in Research issues in aluminum toxicity, (Yokel R. A. and Golub M. S., eds.), Taylor and Francis, Washington DC, pp. 91–116. Harris W. R., Wang Z. and Hamada Y. Z. (2003) Competition between transferrin and the serum ligands citrate and phosphate for the binding of aluminum. Inorg. Chem. 42, 3262–3273. Hartmann A., Hunot S. and Hirsch E. C. (2003) Inflammation and dopaminergic neuronal loss in Parkinson’s disease: a complex matter. Exp. Neurol. 184, 561–564. Hawkes C. H., Del Tredici K. and Braak H. (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33, 599–614. He Y., Appel S. and Le W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909, 187–193. Healy D. G., Abou-Sleiman P. M. and Wood N. W. (2004) Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res. 318, 189–194.
REFERENCES Hegde R., Srinivasula S. M., Zhang Z., Wassell R., Mukattash R., Cilenti L., DuBois G., Lazebnik, Y., Zervos A. S., Fernandes-Alnemri T. and Alnemri E. S. (2002) Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein- caspase interaction. J. Biol. Chem. 277, 432–438. Heikkila R. E., Manzino L., Cabbat F. S. and Duvoisin R. C. (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311, 467–469. Heikkila R. E., Nicklas W. J. and Duvoisin R. C. (1985) Dopaminergic toxicity after the stereotaxic administration of the 1-methyl-4-phenylpyridinium ion (MPP + ) to rats. Neurosci. Lett. 59, 135–140. Hermida-Ameijeiras A., Méndez-Álvarez E., Sánchez-Iglesias S., Sanmartín-Suárez C. and Soto- Otero R. (2004) Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem. Int. 45, 103–116. Hernan M. A., Takkouche B., Caamano-Isorna F. and Gestal-Otero J. J. (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann. Neurol. 52, 276–284. Herrera A. J., Castano A., Venero J. L., Cano J. and Machado A. (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7, 429–447. Hertzman C., Wiens M., Bowering D., Snow B. and Calne D. (1990) Parkinson's disease: a case- control study of occupational and environmental risk factors. Am. J. Ind. Med. 17, 349–355. Hess D. T., Matsumoto A., Kim S. O., Marshall H. E., Stamler J. S. (2005) Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. 6, 150–166. Hilker R., Schweitzer K., Coburger S., et al. (2005) Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62, 378 –382. 203
- Page 176 and 177: SUMMARY values were attained at 48
- Page 178 and 179: SUMMARY neurodegeneration in the DA
- Page 181 and 182: CONCLUSIONS The results obtained in
- Page 183: 13) Aluminium does affect neither M
- Page 187 and 188: RESUMEN RESUMEN Desde el punto de v
- Page 189 and 190: RESUMEN zonas cerebrales excepto en
- Page 191: CONCLUSIONES
- Page 194 and 195: CONCLUSIONES Capítulo 2 4) La admi
- Page 196 and 197: CONCLUSIONES 172 En base a las conc
- Page 199 and 200: Publications as a direct result fro
- Page 201: REFERENCES
- Page 204 and 205: REFERENCES Agil A., Duran R., Barre
- Page 206 and 207: REFERENCES Baquet Z. C., Bickford P
- Page 208 and 209: REFERENCES 184 1,2,3,6-tetrahydropy
- Page 210 and 211: REFERENCES 186 compacta of the subs
- Page 212 and 213: REFERENCES Chung K. K., Dawson V. L
- Page 214 and 215: REFERENCES Davies K. J. (2001) Degr
- Page 216 and 217: REFERENCES Dhillon A. S., Tarbutton
- Page 218 and 219: REFERENCES Ekstrand M. I., Falkenbe
- Page 220 and 221: REFERENCES Fleming S. M., Delville
- Page 222 and 223: REFERENCES Ghribi O., Dewitt D. A.,
- Page 224 and 225: REFERENCES Good P. F., Olanow C. W.
- Page 228 and 229: REFERENCES Hirsch E. C., Brandel J.
- Page 230 and 231: REFERENCES Inden M., Kitamura Y., T
- Page 232 and 233: REFERENCES Johnson V. J. and Sharma
- Page 234 and 235: REFERENCES Kim W. G., Mohney R. P.,
- Page 236 and 237: REFERENCES Kuhn W., Winkel R., Woit
- Page 238 and 239: REFERENCES 214 K.D. and Polymeropou
- Page 240 and 241: REFERENCES Maraganore D. M., Lesnic
- Page 242 and 243: REFERENCES McCord J. M. and Fridovi
- Page 244 and 245: REFERENCES Miu A. C. and Benga O. (
- Page 246 and 247: REFERENCES Nair V. D., McNaught K.,
- Page 248 and 249: REFERENCES Onyango I. G. (2008) Mit
- Page 250 and 251: REFERENCES Perez F. A. and Palmiter
- Page 252 and 253: REFERENCES Przedborski S. and Goldm
- Page 254 and 255: REFERENCES Rifat S. L., Eastwood M.
- Page 256 and 257: REFERENCES Rymar V. V., Sasseville
- Page 258 and 259: REFERENCES Savory J., Herman M. M.
- Page 260 and 261: REFERENCES Shimizu H., Mori T., Koy
- Page 262 and 263: REFERENCES 238 the generation of hy
- Page 264 and 265: REFERENCES Taylor G. A., Moore P. B
- Page 266 and 267: REFERENCES Um J. W., Stichel-Gunkel
- Page 268 and 269: REFERENCES Vila M. and Przedborski
- Page 270 and 271: REFERENCES Whitehead M. W., Farrar
- Page 272 and 273: REFERENCES Yokel R. A. (2002a) Alum
- Page 274: REFERENCES Zhou W., Zhu M., Wilson
REFERENCES<br />
Hegde R., Sr<strong>in</strong>ivasula S. M., Zhang Z., Wassell R., Mukattash R., Cilenti L., DuBois G., Lazebnik,<br />
Y., Zervos A. S., Fernandes-Alnemri T. and Alnemri E. S. (2002) Identification <strong>of</strong> Omi/HtrA2<br />
as a mitochondrial apoptotic ser<strong>in</strong>e protease that disrupts <strong>in</strong>hibitor <strong>of</strong> apoptosis prote<strong>in</strong>-<br />
caspase <strong>in</strong>teraction. J. Biol. Chem. 277, 432–438.<br />
Heikkila R. E., Manz<strong>in</strong>o L., Cabbat F. S. and Duvois<strong>in</strong> R. C. (1984) Protection aga<strong>in</strong>st the<br />
dopam<strong>in</strong>ergic <strong>neurotoxicity</strong> <strong>of</strong> 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrid<strong>in</strong>e by<br />
monoam<strong>in</strong>e oxidase <strong>in</strong>hibitors. Nature 311, 467–469.<br />
Heikkila R. E., Nicklas W. J. and Duvois<strong>in</strong> R. C. (1985) Dopam<strong>in</strong>ergic toxicity after the stereotaxic<br />
adm<strong>in</strong>istration <strong>of</strong> the 1-methyl-4-phenylpyrid<strong>in</strong>ium ion (MPP + ) to rats. Neurosci. Lett. 59,<br />
135–140.<br />
Hermida-Ameijeiras A., Méndez-Álvarez E., Sánchez-Iglesias S., Sanmartín-Suárez C. and Soto-<br />
Otero R. (2004) Autoxidation and MAO-mediated metabolism <strong>of</strong> dopam<strong>in</strong>e as a potential<br />
cause <strong>of</strong> <strong>oxidative</strong> <strong>stress</strong>: role <strong>of</strong> ferrous and ferric ions. Neurochem. Int. 45, 103–116.<br />
Hernan M. A., Takkouche B., Caamano-Isorna F. and Gestal-Otero J. J. (2002) A meta-analysis<br />
<strong>of</strong> c<strong>of</strong>fee dr<strong>in</strong>k<strong>in</strong>g, cigarette smok<strong>in</strong>g, and the risk <strong>of</strong> Park<strong>in</strong>son’s disease. Ann. Neurol. 52,<br />
276–284.<br />
Herrera A. J., Castano A., Venero J. L., Cano J. and Machado A. (2000) The s<strong>in</strong>gle <strong>in</strong>tranigral<br />
<strong>in</strong>jection <strong>of</strong> LPS as a new model for study<strong>in</strong>g the selective effects <strong>of</strong> <strong>in</strong>flammatory reactions<br />
on dopam<strong>in</strong>ergic system. Neurobiol. Dis. 7, 429–447.<br />
Hertzman C., Wiens M., Bower<strong>in</strong>g D., Snow B. and Calne D. (1990) Park<strong>in</strong>son's disease: a case-<br />
control study <strong>of</strong> occupational and environmental risk factors. Am. J. Ind. Med. 17, 349–355.<br />
Hess D. T., Matsumoto A., Kim S. O., Marshall H. E., Stamler J. S. (2005) Prote<strong>in</strong> S-nitrosylation:<br />
purview and parameters. Nat. Rev. Mol. Cell Biol. 6, 150–166.<br />
Hilker R., Schweitzer K., Coburger S., et al. (2005) Nonl<strong>in</strong>ear progression <strong>of</strong> Park<strong>in</strong>son disease<br />
as determ<strong>in</strong>ed by serial positron emission tomographic imag<strong>in</strong>g <strong>of</strong> striatal fluorodopa F 18<br />
activity. Arch. Neurol. 62, 378 –382.<br />
203
Change language